Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
EBioMedicine. 2020 Aug;58:102897. doi: 10.1016/j.ebiom.2020.102897. Epub 2020 Jul 22.
Gene therapy has held promises for treating specific genetic diseases. However, the key to clinical application depends on effective gene delivery.
Using a large animal model, we developed two pharmaceutical formulations for gene delivery in the pigs' vagina, which were made up of poly (β-amino ester) (PBAE)-plasmid polyplex nanoparticles (NPs) based two gel materials, modified montmorillonite (mMMT) and hectorite (HTT).
By conducting flow cytometry of the cervical cells, we found that PBAE-GFP-NPs-mMMT gel was more efficient than PBAE-GFP-NPs-HTT gel in delivering exogenous DNA intravaginally. Next, we designed specific CRISPR/SpCas9 sgRNAs targeting porcine endogenous retroviruses (PERVs) and evaluated the genome editing efficacy in vivo. We discovered that PERV copy number in vaginal epithelium could be significantly reduced by the local delivery of the PBAE-SpCas9/sgRNA NPs-mMMT gel. Comparable genome editing results were also obtained by high-fidelity version of SpCas9, SpCas9-HF1 and eSpCas9, in the mMMT gel. Further, we confirmed that the expression of topically delivered SpCas9 was limited to the vagina/cervix and did not diffuse to nearby organs, which was relatively safe with low toxicity.
Our data suggested that the PBAE-NPs mMMT vaginal gel is an effective preparation for local gene therapy, yielding insights into novel therapeutic approaches to sexually transmitted disease in the genital tract.
This work was supported by the National Science and Technology Major Project of the Ministry of science and technology of China (No. 2018ZX10301402); the National Natural Science Foundation of China (81761148025, 81871473 and 81402158); Guangzhou Science and Technology Programme (No. 201704020093); National Ten Thousand Plan-Young Top Talents of China, Fundamental Research Funds for the Central Universities (17ykzd15 and 19ykyjs07); Three Big Constructions-Supercomputing Application Cultivation Projects sponsored by National Supercomputer Center In Guangzhou; the National Research FFoundation (NRF) South Africa under BRICS Multilateral Joint Call for Proposals; grant 17-54-80078 from the Russian Foundation for Basic Research.
基因治疗在治疗特定遗传疾病方面具有广阔的前景。然而,其临床应用的关键取决于有效的基因传递。
我们使用大型动物模型开发了两种用于阴道内基因传递的药物制剂,它们由基于两种凝胶材料的聚(β-氨基酯)(PBAE)-质粒多聚物纳米颗粒(NPs)组成,分别为改性蒙脱石(mMMT)和水辉石(HTT)。
通过对宫颈细胞进行流式细胞术,我们发现 PBAE-GFP-NPs-mMMT 凝胶在阴道内传递外源性 DNA 方面比 PBAE-GFP-NPs-HTT 凝胶更有效。接下来,我们设计了针对猪内源性逆转录病毒(PERVs)的特定 CRISPR/SpCas9 sgRNA,并在体内评估了基因组编辑的效果。我们发现,通过局部递送 PBAE-SpCas9/sgRNA NPs-mMMT 凝胶可以显著降低阴道上皮中的 PERV 拷贝数。在 mMMT 凝胶中,高保真版本的 SpCas9、SpCas9-HF1 和 eSpCas9 也获得了类似的基因组编辑结果。此外,我们证实,局部递送的 SpCas9 的表达仅限于阴道/宫颈,不会扩散到附近的器官,具有相对较低的毒性,安全性较高。
我们的数据表明,PBAE-NPs mMMT 阴道凝胶是一种有效的局部基因治疗制剂,为生殖道性传播疾病的新型治疗方法提供了思路。
本工作得到了中国科技部国家科技重大专项(No. 2018ZX10301402);国家自然科学基金(81761148025、81871473 和 81402158);广州市科技计划(No. 201704020093);国家万人计划-青年拔尖人才;中央高校基本科研业务费(17ykzd15 和 19ykyjs07);国家超级计算广州中心超级计算应用培育项目;国家自然科学基金委与南非国家研究基金会(NRF)BRICS 多边联合提案;俄罗斯基础研究基金会(NRF)17-54-80078 号基金。